Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Refractory Chronic GVHD
NCT02174263Phase 2Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2016
- Primary completion
- Aug 2019
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in chronic graft-versus-host disease (cGVHD), sponsored by Fred Hutchinson Cancer Center. Planned start Feb 2016; status: withdrawn.
02
Drugs
tocilizumab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02174263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02174263.